TrialsgrambetaRCTs are beautiful

CORP

2011

COlchicine for Recurrent Pericarditis

In 120 patients with a first recurrence of pericarditis, colchicine for 6 months added to conventional anti-inflammatory therapy halved further recurrence at 18 months compared with placebo.

Result

Recurrence rate at 18 months
Absolute difference
31 points
NNT
4
Effect estimate

relative risk reduction0.5695% CI 0.27-0.73

Absolute difference and NNT are derived from the event rates.

Also reported: NNT 3). Side-effect and withdrawal rates similar.

Original publication
Subtopic
Recurrent pericarditis
Design
Double-blind, placebo-controlled RCT
Relevance
Important: one of several pillars.
Source
Imazio M, Brucato A, Cemin R, et al. Ann Intern Med. 2011;155(7):409-414.doi 10.7326/0003-4819-155-7-201110040-00359

Discussion & critique

Small, single-country and restricted to a first recurrence of non-bacterial, non-neoplastic aetiology. It was the first properly blinded randomised demonstration that colchicine prevents relapse and, with ICAP and CORP-2, underpins the class-I recommendation.